Entelos Signs Anemia Research Deal With GlaxoSmithKline
2009年2月4日 - 4:54PM
Dow Jones News
Entelos Inc. (ENTL.LN), which makes software that lets
pharmaceutical companies run "virtual" drug trials using computers,
said Wednesday it signed a research deal with GlaxoSmithKline PLC
(GSK.LN).
GlaxoSmithKline wants to use Entelos' Hematopoeisis PhysioLab
platform to develop drugs for anemia.
Financial terms weren't disclosed.
Company Web site: www.entelos.com
-By Jason Douglas, Dow Jones Newswires; 44-20-7842-9272;
jason.douglas@dowjones.com
Click here to go to Dow Jones NewsPlus, a web front
page of today's most important business and market news, analysis
and commentary. You can use this link on the day this article is
published and the following day.
Entelos Regs (LSE:ENTL)
過去 株価チャート
から 5 2024 まで 6 2024
Entelos Regs (LSE:ENTL)
過去 株価チャート
から 6 2023 まで 6 2024
Real-Time news about Entelos Regs (ロンドン証券取引所): 0 recent articles
その他のEntelos Regsニュース記事